{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:26:16Z","timestamp":1787617576258,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase 2\/JAK1 inhibitor, in participants with mild-to-moderate PsO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase IIb multicentre randomized double-blind study was conducted in two stages. In stage 1, participants received one of eight treatments for 12 weeks: brepocitinib 0.1% once daily, 0.3% once or twice daily, 1.0% once or twice daily, 3.0% once daily, or vehicle once or twice daily. In stage 2, participants received brepocitinib 3.0% twice daily or vehicle twice daily. The primary endpoint was the change from baseline in Psoriasis Area and Severity Index (PASI) score at week 12, analysed using analysis of covariance. The key secondary endpoint was the proportion of participants who achieved a Physician Global Assessment response [score of clear (0) or almost clear (1) and an improvement of \u2265 2 points from baseline] at week 12. Additional secondary endpoints included the difference vs. vehicle in change from baseline in PASI, using mixed-model repeated measures, and the change from baseline in Peak Pruritus Numerical Rating Scale at week 12. Safety was monitored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 344 participants were randomized. Topical brepocitinib did not result in statistically significant changes compared with respective vehicle controls in the primary or key secondary efficacy endpoints for any dose group. At week 12, least squares mean change from baseline in PASI score ranged from \u20131.4 to \u20132.4 for the brepocitinib once-daily groups vs. \u20131.6 for vehicle once daily, and from \u20132.5 to \u20133.0 for the brepocitinib twice-daily groups vs. \u20132.2 for vehicle twice daily. From week 8, change from baseline in PASI score separated from vehicle in all brepocitinib twice daily groups. Brepocitinib was well tolerated, with adverse events (AEs) occurring at similar rates across groups. One participant in the brepocitinib 1.0% once-daily group developed a treatment-related AE of herpes zoster in the neck area.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Topical brepocitinib was well tolerated but did not result in statistically significant changes compared with vehicle when administered at the doses evaluated to treat signs and symptoms of mild-to-moderate PsO.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad098","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T17:35:12Z","timestamp":1679938512000},"page":"33-41","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study"],"prefix":"10.1093","volume":"189","author":[{"given":"Megan N","family":"Landis","sequence":"first","affiliation":[{"name":"Department of Medicine (Dermatology), University of Louisville School of Medicine , Louisville, KY , USA"},{"name":"Dermatology and Skin Cancer Center of South Indiana , Corydon, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy R","family":"Smith","sequence":"additional","affiliation":[{"name":"California Dermatology and Clinical Research Institute , Encinitas, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Berstein","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Fetterly","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeepta","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S","family":"Beebe","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Tarabar","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"2023100915264412300_ljad098-B1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring","volume":"7","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"2023100915264412300_ljad098-B2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2023100915264412300_ljad098-B3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100915264412300_ljad098-B4","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s13555-021-00620-x","article-title":"Characterizing outcomes and unmet needs among patients in the United States with mild-to-moderate plaque psoriasis using prescription topicals","volume":"11","author":"Gupta","year":"2021","journal-title":"Dermatol Ther (Heidelb"},{"key":"2023100915264412300_ljad098-B5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-0625.2011.01335.x","article-title":"Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography","volume":"20","author":"Aschoff","year":"2011","journal-title":"Exp Dermatol"},{"key":"2023100915264412300_ljad098-B6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0019-5154.139872","article-title":"Topical steroid-damaged skin","volume":"59","author":"Abraham","year":"2014","journal-title":"Indian J Dermatol"},{"key":"2023100915264412300_ljad098-B7","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2023100915264412300_ljad098-B8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100915264412300_ljad098-B9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100915264412300_ljad098-B10","author":"Dermavant"},{"key":"2023100915264412300_ljad098-B11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2023100915264412300_ljad098-B12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"2023100915264412300_ljad098-B13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100915264412300_ljad098-B14","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023100915264412300_ljad098-B15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023100915264412300_ljad098-B16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023100915264412300_ljad098-B17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023100915264412300_ljad098-B18","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023100915264412300_ljad098-B19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2023100915264412300_ljad098-B20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"issue":"15","key":"2023100915264412300_ljad098-B21","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"2023100915264412300_ljad098-B22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023100915264412300_ljad098-B23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100915264412300_ljad098-B24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2012signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100915264412300_ljad098-B25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100915264412300_ljad098-B26","author":"PubChem"},{"key":"2023100915264412300_ljad098-B27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"2023100915264412300_ljad098-B28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023100915264412300_ljad098-B29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2023100915264412300_ljad098-B30","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad098\/50332584\/ljad098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/33\/51959203\/ljad098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/33\/51959203\/ljad098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:28:19Z","timestamp":1696865299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/1\/33\/7087205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad098","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,3,27]]}}}